EN
NEWS
Company News
06.042019
New GMP manufacturing facility launched
In May 2019, TCRCure opened a new research and manufacturing site in the Los Angeles bioscience corridor. The 5000 square foot facility includes 1400 s.f. of GMP-compliant manufacturing space and 1000 s.f. of R&D space, plus additional flex space. Patient cell therapy products will be produced in a 600 square foot ISO 7 cleanroom according to cGMPs for cell-therapy manufacturing. It will be TCRCure’s major site for clinical-grade therapeutic production in the US.
  • 06.122019
    GMP certified Guangdong manufacturing site construction launched
    TCRCure’s Guangdong manufacturing site, which includes GMP certified cell production facilities, office space, and labs for quality assurance, research and development, launched construction in Guangdong Medical Valley.
  • 06.042019
    New GMP manufacturing facility launched
    In May 2019, TCRCure opened a new research and manufacturing site in the Los Angeles bioscience corridor. The 5000 square foot facility includes 1400 s.f. of GMP-compliant manufacturing space and 1000 s.f. of R&D space, plus additional flex space. Patient cell therapy products will be produced in a 600 square foot ISO 7 cleanroom according to cGMPs for cell-therapy manufacturing. It will be TCRCure’s major site for clinical-grade therapeutic production in the US.
  • 12.282018
    TCRCure completes series B funding
    In December 2018, TCRCure closed series B funding with hundreds of millions of US dollars , led by major venture capital firms including many famous professional healthcareinvestors in the United States and China.
  • 11.022018
    TCRCure Chongqing Research Institute passes certification of quality, environmental, and occupational health and safety.
    TCRCure Chongqing Research Institute passes certification of quality, environmental, and occupational health and safety.
  • 05.282018
    TCRCure Chongqing Research Institute awarded Chongqing postdoctoral program
    TCRCure Chongqing Research Institute was officially awarded the Chongqing Postdoctoral Program by the Chongqing Municipal Human Resources and Social Security Bureau on May 18, 2019.
  • 05.162018
    TCRCure completes series A funding
    In April 2018, TCRCure closed series A funding,led by major venture capital firms including many famous professional healthcareinvestors in the United States and China.
1
More

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
Introduction to TCRCure
Immune Cell Therapy
Product and Services
News
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer